Eli Lilly (LLY) Stock Hits Record High After European Drug Approval and Medicare Expansion

Key Highlights

• LLY shares climbed approximately 6% on June 26 following positive recommendation from the European Medicines Agency for Jaypirca in leukemia patients
• A new Medicare GLP-1 Bridge initiative launching July 1 will provide Zepbound and Foundayo access for a $50 monthly patient contribution
• Analysts at Leerink Partners increased their LLY price target to $1,232 after these developments
• LLY shares rose 9.62% in the past week and reached a fresh 52-week peak of $1,206
• The company discontinued an early-stage prostate cancer trial combining abemaciclib with darolutamide

Eli Lilly shares experienced remarkable strength this past week. Multiple regulatory developments and clinical updates propelled LLY upward by 9.62% across seven trading sessions, culminating in a new 52-week peak of $1,206.

Eli Lilly and Company, LLY

The most significant daily gain occurred on June 26, when LLY climbed roughly 6%. This surge was triggered by the European Medicines Agency’s Committee for Medicinal Products for Human Use delivering a favorable recommendation for Jaypirca (pirtobrutinib) as a treatment option for chronic lymphocytic leukemia.

A favorable recommendation from the EMA generally represents the final hurdle before receiving European Commission authorization, which typically follows within a two-month timeframe. With Jaypirca already authorized by the FDA for U.S. distribution, European approval would unlock an additional significant market opportunity for this oncology therapy.

In response to these developments, Leerink Partners increased their price objective for LLY shares to $1,232.

New Medicare Weight Loss Drug Program Boosts Investor Confidence

Concurrent with the cancer drug developments, Medicare revealed a new GLP-1 Bridge initiative scheduled to begin July 1, 2026. This program will enable qualified beneficiaries to obtain Lilly’s obesity medications Zepbound and Foundayo for a $50 monthly patient contribution.

This represents a substantial cost reduction for numerous patients and may catalyze a significant increase in prescription volumes. Enhanced accessibility to GLP-1 therapies has emerged as a critical focus for investors monitoring Lilly’s obesity treatment portfolio.

The simultaneous announcement of the European regulatory advancement and the Medicare accessibility program on the same day provided investors with dual catalysts for optimism.

Clinical Development Progress Spanning Multiple Disease Categories

Beyond these immediate catalysts, Lilly provided investors with updates on two Phase 3 clinical studies evaluating donanemab for Alzheimer’s disease. One trial is assessing the therapy in preclinical Alzheimer’s patients within China. The second is investigating whether once-yearly administration can maintain therapeutic benefits in patients who demonstrated prior positive responses.

LLY additionally initiated a Phase 3 clinical trial for orforglipron, an oral formulation GLP-1 medication, targeting pediatric Type 2 diabetes patients. This advancement extends its metabolic disease development portfolio beyond adult populations.

Not all pipeline news was favorable. A Phase 1b clinical study evaluating the combination of abemaciclib and darolutamide in metastatic castration-resistant prostate cancer was halted prematurely, representing a disappointment in that particular oncology indication. Investors largely overlooked this setback considering the breadth of other pipeline advancement.

Earlier this month, Lilly disclosed favorable Phase 3 clinical results for retatrutide, its advanced-generation obesity medication that targets three hormone receptors — GIP, GLP-1, and glucagon. These findings were unveiled at the American Diabetes Association’s 86th Scientific Sessions on June 6 and subsequently published in The Lancet. Previous Phase 3 results demonstrated 24.2% weight reduction at 72 weeks in patients with cardiovascular disease and 28.7% weight loss in individuals with knee osteoarthritis.

LLY shares have appreciated 11.7% year-to-date. Analysts collectively maintain a consensus “Strong Buy” recommendation on the stock. As of Friday’s market close, Lilly reached $1,206 per share — establishing a new 52-week high.